Moteur de recherche d’entreprises européennes
Financement de l’UE (9 664 970 €) : Big Data 4 Better Hearts - Sofia réf. : 116074 Hor01/03/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Big Data 4 Better Hearts - Sofia réf. : 116074
Despite remarkable progress in the management of cardiovascular disease (CVD), major unmet needs remain with regard to mortality, hospitalisations, quality of life (QoL), healthcare expenditures and productivity. Acute coronary syndrome (ACS), atrial fibrillation (AF) and heart failure (HF) are major and growing components of the global CVD burden. Optimal management of these conditions is complicated by their complex aetiology and heterogeneous prognoses. Poor definition at the molecular level and co/multi-morbidities form major challenges for the development and delivery of targeted treatments. This renders response to therapy unpredictable, with large inter-individual variation and, importantly, small or undetectable treatment effects in large trials of unselected patients. Today’s treatment guidelines still reflect the scientific constraints of an earlier era where clinical markers to guide therapy are limited to conventional risk factors and end-organ damage, and where the main endpoint in clinical trials is patient death. Hence, drug development pipelines from early target validation through to late post-marketing work have proven to be slow, expensive and high-risk: the chance of eventual approval for a CVD drug candidate in Phase I trials is 7%, the lowest of any disease category (shared with oncology) 2. Moreover, tolerability of medication and adherence to treatment show wide variations. There is thus a need for better definition of these diseases, their markers and endpoints (including better segmentation of current heterogeneous patient groups acknowledging underlying mechanisms and comorbidities) and of their outcomes/prognoses (including functional capacity and quality of life [QoL]). BigData@Heart’s ultimate goal is to develop a Big Data--driven translational research platform of unparalleled scale and phenotypic resolution in order to deliver clinically relevant disease phenotypes, scalable insights from real-world evidence and insights driving
| BAYER AG | 0,00 € |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | 1 049 375 € |
| European Heart Network Aisbl | 150 800 € |
| Fundacion para La Investigacion del Hospital Clinico de La Comunitat Valenciana, Fundacion Incliva | 386 250 € |
| Institut de Recherches Internationales Servier | 0,00 € |
| INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT Inc. | 319 375 € |
| International Consortium for Healthoutcomes Measurement Ltd. | 0,00 € |
| Karolinska Institutet | 250 000 € |
| NOVARTIS PHARMA AG | 0,00 € |
| Region Stockholm | 0,00 € |
| Region Uppsala | 200 000 € |
| SE de Cardiologie | 617 035 € |
| SOMALOGIC Inc. | 0,00 € |
| STICHTING MLC Foundation | 116 812 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 670 281 € |
| THE HYVE B.V. | 376 250 € |
| The University of Birmingham | 468 927 € |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | 386 250 € |
| UNIVERSITAIR MEDISCH CENTRUM UTRECHT | 3 296 187 € |
| University College London | 1 377 428 € |
| Uppsala Universitet | 0,00 € |
| VIFOR (INTERNATIONAL) AG | 0,00 € |
https://cordis.europa.eu/project/id/116074
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.